Skip to main content
. 2007 Aug;61(8):1256–1269. doi: 10.1111/j.1742-1241.2007.01458.x

Table 6.

Summary of adverse events (safety sample)*

Indoprocaf (n = 143) Sumatriptan (n = 139)
Patients reporting at least one TEAE (n, %) 31 (22) 25 (18)
Patients reporting at least one related TEAE (n, %) 23 (16) 14 (10)
Serious adverse events (n)  1
Patients dropped-out as a result of adverse events (n)  3  1
*

Indoprocaf indicates indomethacin, prochlorperazine and caffeine; TEAE indicates treatment-emergent adverse events.